Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Shares Outstanding (Diluted Average) (2017 - 2025)

ProQR Therapeutics' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $122.6 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 33.29% to $122.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $122.6 million, a 33.29% increase, with the full-year FY2025 number at $122.6 million, up 33.29% from a year prior.
  • Shares Outstanding (Diluted Average) hit $122.6 million in Q4 2025 for ProQR Therapeutics, up from $374.1 in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for PRQR hit a ceiling of $122.6 million in Q4 2025 and a floor of $97.77 in Q1 2024.
  • Historically, Shares Outstanding (Diluted Average) has averaged $18.7 million across 5 years, with a median of $339.45 in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 6655431.46% in 2022 and later crashed 58.01% in 2023.
  • Tracing PRQR's Shares Outstanding (Diluted Average) over 5 years: stood at $1098.2 in 2021, then skyrocketed by 6655431.46% to $73.1 million in 2022, then rose by 19.25% to $87.2 million in 2023, then increased by 5.54% to $92.0 million in 2024, then surged by 33.29% to $122.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for PRQR at $122.6 million in Q4 2025, $374.1 in Q3 2025, and $237.71 in Q2 2025.